In vitro effects of beta-carotene on human oral keratinocytes from precancerous lesions and squamous carcinoma.

S. Toma, E. Albanese, R. Palumbo, G. Nicoló, C. Morerio, P. E. Magiante, S. Bonatti, R. Cancedda, L. Santi

Research output: Contribution to journalArticle

Abstract

Human keratinocytes, obtained from bioptic specimens of healthy and preneoplastic oral mucosa, and from human cell lines from oral cavity tumors (KB and SCC-25) were treated with beta-carotene (10 microM). The colony forming efficiency (CFE), the proliferation rate and the frequency of micronucleated cells were measured in these cultures. CFE was significantly reduced (p less than 0.05) by beta-carotene treatment in cells from healthy mucosa and in KB cells. Decreases (p greater than 0.05; NS) were also observed in cells from pathological mucosa and in SCC-25 cells. Cell proliferation rate was not substantially affected by beta-carotene in all cultures. Finally, a decreased frequency of micronucleated cells was found in treated cultures, but significant reductions (p less than 0.05) were only observed in cultures from oral mucosa (healthy and pathological) as well as in KB cell cultures. Our results indicate that beta-carotene is able to reduce the clonogenic activity (CFE), even if it does not seem to influence cell proliferation, and that it has a protective effect against genotoxic damage.

Original languageEnglish
Pages (from-to)581-589
Number of pages9
JournalAnti-Cancer Drugs
Volume2
Issue number6
Publication statusPublished - Dec 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'In vitro effects of beta-carotene on human oral keratinocytes from precancerous lesions and squamous carcinoma.'. Together they form a unique fingerprint.

  • Cite this

    Toma, S., Albanese, E., Palumbo, R., Nicoló, G., Morerio, C., Magiante, P. E., Bonatti, S., Cancedda, R., & Santi, L. (1991). In vitro effects of beta-carotene on human oral keratinocytes from precancerous lesions and squamous carcinoma. Anti-Cancer Drugs, 2(6), 581-589.